# 2025-11809: FDA Guidance Focuses on Lyme's Tell-Tale Expanding Rash

2025-11809, Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment; Guidance for Industry; Availability, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-06-26, effective 2025-06-26 (as of 2026-11-05).

- Canonical: https://policyrisk.com/federal-register/2025-11809
- As of: 2026-11-05
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-11809
- Title: Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment; Guidance for Industry; Availability
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 27320
- Published: 2025-06-26
- Effective: 2025-06-26
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-11-05

## In one line

FDA Guidance Focuses on Lyme's Tell-Tale Expanding Rash

## Summary

The FDA just released final guidance to help drug makers create better treatments for early Lyme disease, especially when it shows up as a rash called erythema migrans. This update affects companies developing Lyme disease drugs and aims to speed up safe, effective treatments hitting the market. The guidance is official as of June 26, 2025, and companies can comment anytime, making it easier and clearer to fight Lyme disease early on.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Early Lyme Disease as Manifested by Erythema Migrans: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the clinical development of drugs for the treatment of early Lyme disease as manifested by erythema migrans (EM). This guidance finalizes the draft guidance of the same name issued on February 1, 2023.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-11809 on federalregister.gov](https://www.federalregister.gov/documents/2025/06/26/2025-11809/early-lyme-disease-as-manifested-by-erythema-migrans-developing-drugs-for-treatment-guidance-for)
- [2025-11809 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-06-26/pdf/2025-11809.pdf)

## Related
- [Previous: 2025-11808, Elimination of Green and Energy Efficient Mortgage Insurance Premium Rate Categ…](https://policyrisk.com/federal-register/2025-11808)
- [Next: 2025-11810, South Atlantic Fishery Management Council (Council); Public Meetings](https://policyrisk.com/federal-register/2025-11810)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-11809 (as of 2026-11-05).
